Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

ImmunoCellular Therapeutics provides update on phase III ICT-107 study

Jan. 24, 2012

Interim results reported from phase I/IIa ensituximab trial

Jan. 24, 2012

Enrollment opens in phase III PRESENT study of NeuVax

Jan. 23, 2012

Fifth Merrimack Pharmaceuticals program advances to clinic

Jan. 16, 2012

Treatment begins in phase II study of Advaxis' ADXS-HPV

Jan. 16, 2012

First-in-human data disclosed on ALT-801

Jan. 11, 2012

Circadian Technologies initiates first clinical study of VGX-100

Jan. 9, 2012

Celldex begins phase II study of rindopepimut

Jan. 5, 2012

Generex provides update on second-generation peptide vaccine for cancer

Jan. 4, 2012

Amgen moves AMG-172 to clinic

Jan. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
New biomarker may improve RSV drug screening
BioWorld
Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...